The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 1, 2014, Pages 46-51

  Waters, Alicia M ^a   Beierle, Elizabeth A ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

FAK; Mdm2; MYCN; Neuroblastoma; P53

Indexed keywords

2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; NUTLIN 3; NVP TAE226; OKADAIC ACID; PF 228; PF 573; PROTEIN MDM2; PROTEIN P53; RG7112; UNCLASSIFIED DRUG; Y15;

CARCINOGENESIS; CELL SURVIVAL; GENE INTERACTION; GENE MUTATION; HUMAN; MYCN GENE; NEUROBLASTOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899463559     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113136660331     Document Type: Review

References (55)

1. Cotterill, S.J.; Parker, L.; More, L.; Craft, A.W. Neuroblastoma: changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry. Med. Pediatr. Oncol., 2001, 36 (1), 231-234.
2. Cheung, N.K.; Dyer, M.A. Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nat. Rev. Cancer, 2013, 13 (6), 397-411.
3. De Bernardi, B.; Rogers, D.; Carli, M.; Madon, E.; De Laurentis, T.; Bagnulo, S.; Di Tullio, M.T.; Paolucci, G.; Pastore, G. Localized neuroblastoma. Surgical and pathologic staging. Cancer, 1987, 60 (5), 1066-1072.
4. Brodeur, G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer, 2003, 3 (3), 203-216.
5. Park, J.R.; Eggert, A.; Caron, H. Neuroblastoma: Biology, prognosis, and treatment. Pediatr. Clin. North Am., 2008, 55 (1), 97-120.
6. Blackwood, E.M.; Eisenman, R.N. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science, 1991, 251 (4998), 1211-1217.
7. Brodeur, G.M.; Seeger, R.C.; Schwab, M.; Varmus, H.E.; Bishop, J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 1984, 224 (4653), 1121-1124.
8. Chen, L.; Iraci, N.; Gherardi, S.; Gamble, L.D.; Wood, K.M.; Perini, G.; Lunec, J.; Tweddle, D.A. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res., 2010, 70 (4), 1377-1388.
9. Vasudevan, S.A.; Nuchtern, J.G.; Shohet, J.M. Gene profiling of high risk neuroblastoma. World J. Surg., 2005, 29 (3), 317-324.
10. Seeger, R.C.; Brodeur, G.M.; Sather, H.; Dalton, A.; Siegel, S.E.; Wong, K.Y.; Hammond, D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med., 1985, 313 (18), 1111-1116.
11. Maris, J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatr., 2005, 17 (1), 7-13.
12. Riley, R.D.; Heney, D.; Jones, D.R.; Sutton, A.J.; Lambert, P.C.; Abrams, K.R.; Young, B.; Wailoo, A.J.; Burchill, S.A. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin. Cancer Res., 2004, 10 (1 Pt 1), 4-12.
13. Tanaka, N.; Fukuzawa, M. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells. Int. J. Oncol., 2008, 33 (4), 815-821.
14. Kang, J.H.; Rychahou, P.G.; Ishola, T.A.; Qiao, J.; Evers, B.M.; Chung, D.H. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem. Biophys. Res. Commun., 2006, 351 (1), 192-197.
15. Zhu, Q.; Feng, C.; Liao, W.; Zhang, Y.; Tang, S. Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model. Cancer Cell Int., 2013, 13 (1), 65-70.
16. Schlaepfer, D.D.; Hauck, C.R.; Sieg, D.J. Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol., 1999, 71 (3-4), 435-478.
17. Parsons, J.T. Focal adhesion kinase: The first ten years. J. Cell Sci., 2003, 116 (Pt 8), 1409-1416.
18. Owens, L.V.; Xu, L.; Craven, R.J.; Dent, G.A.; Weiner, T.M.; Kornberg, L.; Liu, E.T.; Cance, W.G. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res., 1995, 55 (13), 2752-2755.
19. Beierle, E.A.; Massoll, N.A.; Hartwich, J.; Kurenova, E.V.; Golubovskaya, V.M.; Cance, W.G.; McGrady, P.; London, W.B. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin. Cancer Res., 2008, 14 (11), 3299-3305.
20. Beierle, E.A.; Trujillo, A.; Nagaram, A.; Kurenova, E.V.; Finch, R.; Ma, X.; Vella, J.; Cance, W.G.; Golubovskaya, V.M. N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J. Biol. Chem., 2007, 282 (17), 12503-12516.
21. Beierle, E.A.; Ma, X.; Stewart, J.; Nyberg, C.; Trujillo, A.; Cance, W.G.; Golubovskaya, V.M. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle, 2010, 9 (5), 1005-1015.
22. Liu, T.J.; LaFortune, T.; Honda, T.; Ohmori, O.; Hatakeyama, S.; Meyer, T.; Jackson, D.; de Groot, J.; Yung, W.K. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol. Cancer Ther., 2007, 6 (4), 1357-1367.
23. Beierle, E.A.; Trujillo, A.; Nagaram, A.; Golubovskaya, V.M.; Cance, W.G.; Kurenova, E.V. TAE226 inhibits human neuroblastoma cell survival. Cancer Invest., 2008, 26 (2), 145-151.
24. Kim, B.; van Golen, C.M.; Feldman, E.L. Degradation and dephosphorylation of focal adhesion kinase during okadaic acid-induced apoptosis in human neuroblastoma cells. Neoplasia, 2003, 5 (5), 405-416.
25. Slack-Davis, J.K.; Martin, K.H.; Tilghman, R.W.; Iwanicki, M.; Ung, E.J.; Autry, C.; Luzzio, M.J.; Cooper, B.; Kath, J.C.; Roberts, W.G.; Parsons, J.T. Cellular characterization of a novel focal adhesion kinase inhibitor. J. Biol. Chem., 2007, 282 (20), 14845-14852.
26. Megison, M.L.; Stewart, J.E.; Nabers, H.C.; Gillory, L.A.; Beierle, E.A. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin. Exp. Metastasis, 2013, 30 (5), 555-568.
27. Schaller, M.D.; Hildebrand, J.D.; Shannon, J.D.; Fox, J.W.; Vines, R.R.; Parsons, J.T. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol. Cell Biol., 1994, 14 (3), 1680-1688.
28. Kim, S.; Hu, W.; Kelly, D.R.; Hellmich, M.R.; Evers, B.M.; Chung, D.H. Gastrin-releasing peptide is a growth factor for human neuroblastomas. Ann. Surg., 2002, 235 (5), 621-630.
29. Lee, S.; Qiao, J.; Paul, P.; O'Connor, K.L.; Evers, M.B.; Chung, D.H. FAK is a critical regulator of neuroblastoma liver metastasis. Oncotarget, 2012, 3 (12), 1576-1587.
30. Chen, L.; Tweddle, D.A. P53, SKP2, and DKK3 as MYCN target genes and their potential therapeutic significance. Front. Oncol., 2012, 2, 1-27.
31. Miyashita, T.; Krajewski, S.; Krajewska, M.; Wang, H.G.; Lin, H.K.; Liebermann, D.A.; Hoffman, B.; Reed, J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 1994, 9 (6), 1799-1805.
32. Brown, C.J.; Lain, S.; Verma, C.S.; Fersht, A.R.; Lane, D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer, 2009, 9 (12), 862-873.
33. Hosoi, G.; Hara, J.; Okamura, T.; Osugi, Y.; Ishihara, S.; Fukuzawa, M.; Okada, A.; Okada, S.; Tawa, A. Low frequency of the p53 gene mutations in neuroblastoma. Cancer, 1994, 73 (12), 3087-3093.
34. Tweddle, D.A.; Malcolm, A.J.; Bown, N.; Pearson, A.D.; Lunec, J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res., 2001, 61 (1), 8-13.
35. Sidell, N.; Koeffler, H.P. Modulation of Mr 53,000 protein with induction of differentiation of human neuroblastoma cells. Cancer Res., 1988, 48 (8), 2226-2230.
36. Chen, L.; Malcolm, A.J.; Wood, K.M.; Cole, M.; Variend, S.; Cullinane, C.; Pearson, A. D.; Lunec, J.; Tweddle, D.A. P53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle, 2007, 6 (21), 2685-2696.
37. Tweddle, D.A.; Malcolm, A.J.; Cole, M.; Pearson, A.D.; Lunec, J. P53 cellular localization and function in neuroblastoma: Evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am. J. Pathol., 2001, 158 (6), 2067-2077.
38. Crook, T.; Fisher, C.; Masterson, P.J.; Vousden, K.H. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene, 1994, 9 (4), 1225-1230.
39. Keshelava, N.; Zuo, J.J.; Waidyaratne, N.S.; Triche, T.J.; Reynolds, C.P. P53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med. Pediatr. Oncol., 2000, 35 (6), 563-568.
40. Marine, J.C.; Francoz, S.; Maetens, M.; Wahl, G.; Toledo, F.; Lozano, G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ., 2006, 13 (6), 927-934.
41. Vousden, K.H.; Lane, D.P. P53 in health and disease. Nat. Rev. Mol. Cell Biol., 2007, 8 (4), 275-283.
42. Jones, S.N.; Hancock, A.R.; Vogel, H.; Donehower, L.A.; Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA, 1998, 95 (26), 15608-15612.
43. Bond, G.L.; Hu, W.; Bond, E.E.; Robins, H.; Lutzker, S.G.; Arva, N.C.; Bargonetti, J.; Bartel, F.; Taubert, H.; Wuerl, P.; Onel, K.; Yip, L.; Hwang, S.J.; Strong, L.C.; Lozano, G.; Levine, A.J. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119 (5), 591-602.
44. Terzian, T.; Wang, Y.; Van Pelt, C.S.; Box, N.F.; Travis, E.L.; Lozano, G. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol. Cell Biol., 2007, 27 (15), 5479-5485.
45. Van Maerken, T.; Rihani, A.; Dreidax, D.; De Clercq, S.; Yigit, N.; Marine, J.C.; Westermann, F.; De Paepe, A.; Vandesompele, J.; Speleman, F. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol. Cancer Ther., 2011, 10 (6), 983-993.
46. Tovar, C.; Graves, B.; Packman, K.; Filipovic, Z.; Higgins, B.; Xia, M.; Tardell, C.; Garrido, R.; Lee, E.; Kolinsky, K.; To, K.H.; Linn, M.; Podlaski, F.; Wovkulich, P.; Vu, B.; Vassilev, L.T. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res., 2013, 73 (8), 2587-2597.
47. Van Maerken, T.; Vandesompele, J.; Rihani, A.; De Paepe, A.; Speleman, F. Escape from p53-mediated tumor surveillance in neuroblastoma: Switching off the p14(ARF)-MDM2-p53 axis. Cell Death Differ., 2009, 16 (12), 1563-1572.
48. Tao, W.; Levine, A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA, 1999, 96 (12), 6937-6941.
49. Golubovskaya, V.; Kaur, A.; Cance, W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim. Biophys. Acta, 2004, 1678 (2-3), 111-125.
50. Golubovskaya, V.M.; Cance, W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front. Biosci., 2010, 15, 901-912.
51. Megison, M.L.; Gillory, L.A.; Beierle, E.A. Cell survival signaling in neuroblastoma. Anticancer Agents Med. Chem., 2013, 13 (4), 563-575.
52. Slack, A.; Chen, Z.; Tonelli, R.; Pule, M.; Hunt, L.; Pession, A.; Shohet, J.M. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc. Natl. Acad. Sci. USA, 2005, 102 (3), 731-736.
53. Gu, L.; Zhang, H.; He, J.; Li, J.; Huang, M.; Zhou, M. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Oncogene, 2012, 31 (11), 1342-1353.
54. He, S.; Liu, Z.; Oh, D.Y.; Thiele, C.J. MYCN and the epigenome. Front. Oncol., 2013, 3, 1-9.
55. Lim, S.T.; Chen, X.L.; Lim, Y.; Hanson, D.A.; Vo, T.T.; Howerton, K.; Larocque, N.; Fisher, S.J.; Schlaepfer, D.D.; Ilic, D. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol. Cell, 2008, 29 (1), 9-22.